April 15, 2009 DURB Meeting Summary

Issue	Attachment*	Action	Notes
Roll Call			Present: Dr. Swee, Dr. Marcus, Mr. Schafer, Ms. Olson, Ms. Martinez- Rodriguez, Dr. Barberio, Dr. Gooen, Dr. Zanna, Dr. Gochfeld Absent: Dr. Woodward, Dr. Lichtbroun, Dr. Moynihan, Dr. Moore, Dr. Condoluci
Review of Minutes	Pages 5-8; Tab 1	Approved	Minutes from March 11, 2009 meeting were approved and will be posted to the DURB website: http://www.nj.gov/humanservices/dmahs/durb_meetings.html
Secretary's Report	Page 9-10; Tab 2		The State will develop a newsletter to inform Medicaid providers of coverage pertaining to over-the-counter nicotine replacement therapy products. This newsletter will be presented to the Board for their comments. High dose proton pump inhibitor protocol has been implemented with the addition of esophageal stents to criteria for approval. Duplication table update with nutritionals and vitamins is currently being programmed.
Business			
A. First Data Bank (FDB) Maximum Daily Dose Standards	Pages 11-12; Tab 3	Approved	DMAHS is pursuing an initiative to incorporate FDB standards into the Medical Exceptions Program (MEP)-Drug Utilization Review (DUR) process. The purpose of this initiative is to enhance the current DUR process to ensure appropriate utilization of drugs and ensure patient safety. Utilizing these standards will assist DMAHS in identifying and ultimately decreasing fraud, waste, and abuse. DMAHS presented the FDB standards to the Board for their review and recommendations/comments/suggestions where necessary. All Board members received CDs with all the maximum daily dose and gender standards. The Board will review medications in the following therapeutic classes: HIV, mental health, and oncology. The Board is

***refers to Pages and Tabs in April 15 DURB Agenda**

April 15, 2009 DURB Meeting Summary

Issue	Attachment*	Action	Notes
			requested to present their finding during the June 2009 meeting.
B. Update to duplication edit	Pages 13-18; Tab 4	Approved	The Board agreed that adding insulin products to the duplication table will enhance the DUR process. This will ultimately prevent patients from obtaining two of the same kinds of medications and will notify the prescribers of possible duplication in therapy.
C. Lidoderm® Protocol	Pages 19-20; Tab 5	Approved	The Board approved the proposed quantity limit for Lidoderm® 5% patches. Patients will be limited to three patches per day. This quantity limit is consistent with FDB maximum doses.
D. Anticoagulants-Low Molecular Weight Heparin (LMWH) and Factor Xa Inhibitor Protocol	Pages 21-24; Tab 6	Approved	LMWH and Factor Xa inhibitor will be added to the therapy duration table. LMWH will initially be approved for use up to 40 days and factor Xa inhibitor will initially be approved for use up to 35 days. Approval beyond these limits for patients will be granted when medically indicated after re-evaluation by the prescriber(s).
Informational Highlights			
1. Unisys Prior Authorization Reporting	Pages 25-28; Tab 7		Unisys is continuously improving the report presented to the Board. "Directed Intervention" has been combined with other appropriate clinical denial categories in an effort to clarify the report.
2. Top Drug Reports	Pages 29-36; Tab 8		The State will attempt to provide these reports carving out institutional patients. This report then may provide the State and the Board with top drugs more frequently utilized by Medicaid, PAAD, SG, ADDP, and GA clients residing in the community setting.
Follow-up Items			
DURB SFY 2008 annual report			The DURB annual report has been signed by the Commissioner, Dept. of Human services and is currently being reviewed by the Commissioner, Dept. of Health & Senior Services for approval.
HMO Denial Reporting			The State requested that the Managed Care Organizations provide a format for quarterly denials that is similar to the Unisys report. These will be presented when the reports are in for the Board's information. First quarter 2009 reports may be provided to the Board during the June 2009 meeting.

***refers to Pages and Tabs in April 15 DURB Agenda**

April 15, 2009 DURB Meeting Summary

Issue	Attachment*	Action	Notes
FDB Maximum Doses			The Chairman has requested the Board members present a report on their progress related to review of FDB maximum doses for the targeted therapeutic classes.
Retro-DUR Compliance Notification			The State will be working with Unisys to set up a process by which compliance letters can be sent to patients' prescribers concerning specific disease states. The disease states of interest include Asthma, Diabetes, Hypertension, Warfarin, and HIV-AIDS.

***refers to Pages and Tabs in April 15 DURB Agenda**